SCHEMBL6474430

SCHEMBL6474430

CCCS(=O)(=O)NCC(C)Oc1ccc(-c2cccc(N)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.40
CA12 O43570 2/20 0.40
CA2 P00918 2/20 0.40
GRIA4 P48058 2/20 0.40
CA1 P00915 1/20 0.40
CA9 Q16790 1/20 0.40
MTNR1A P48039 4/20 0.37
MTNR1B P49286 4/20 0.37
PLK4 O00444 1/20 0.35
DCLK1 O15075 1/20 0.35
DAPK3 O43293 1/20 0.35
DYRK3 O43781 1/20 0.35
JAK2 O60674 1/20 0.35
ROCK2 O75116 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
CDK1 P06493 1/20 0.35
ROS1 P08922 1/20 0.35
PRKACA P17612 1/20 0.35
RPS6KB1 P23443 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474047 0.87 PPARG (0.44) CA12CA2GRIA4MTNR1AMTNR1B
SCHEMBL6475297 0.87 GRIA4 (0.48) GRIA4MTNR1AMTNR1BMAPT
SCHEMBL6482324 0.87 GRIA4 (0.46) CA12CA2GRIA4MTNR1AMTNR1B
SCHEMBL6474263 0.86 GRIA4 (0.40) GRIA4MTNR1AMTNR1BADRB3
SCHEMBL6474219 0.86 MTNR1A (0.50) PLAUGRIA4MTNR1AMTNR1B
SCHEMBL6479543 0.86 GRIA4 (0.45) GRIA4MTNR1AMTNR1BMAPTMAP2K4
SCHEMBL6481819 0.85 SMN1; SMN2 (0.44) GRIA4PLK4DCLK1DAPK3DYRK3
SCHEMBL6474424 0.85 GRIA4 (0.49) PLAUCA12CA2GRIA4CA1
SCHEMBL6481274 0.84 CA12 (0.41) CA12CA2GRIA4CA1CA9
SCHEMBL6479531 0.84 KIF11 (0.46) GRIA4CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 PLAU 4010/4885CA12 2263/4885CA2 1773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.